Vizgen joins EMBL science-industry programme
US-based spatial genomics firm joins as corporate-level supporter
Vizgen, the life science company dedicated to improving human health by visualising single-cell spatial genomics information, has joined EMBL’s Corporate Partnership Programme (CPP).
CPP members benefit from direct connection with EMBL’s world-leading molecular biology and technology development, and their support enables EMBL to provide additional training opportunities for the next generation of molecular life scientists.
“We look forward to the ways in which our scientists and Vizgen’s can share ideas and technology for this promising field of spatially resolved genomics to ultimately advance our understanding of biology acting in situ.” said Vladimir Benes, head of EMBL’s Genomics Core Facility. “Together with Vizgen, we will pursue various educational, methodological, and career development activities.”
“Vizgen is proud to join EMBL’s Corporate Partnership Programme,” said Terry Lo, Vizgen President and CEO. “We look forward to working alongside the organisation to further the development and global reach of the spatial genomics industry.”
CPP members support EMBL’s scientific training and conferences programme, as well as the scientific visitor programme, with CPP fellowships to enable attendance and by participating in discussions of future conference topics and practical courses.
“With Vizgen’s support, EMBL can extend access to our world-class scientific gatherings to scientists who otherwise might not be able to participate,” said Nadine Ilk, CPP manager. “This gives these scientists the opportunity to contribute to and participate in advanced scientific training.”
Ilk emphasised that the CPP was designed to form and cultivate long-term, fruitful relationships between EMBL and top-class corporate partners.
Members also access tailored opportunities to engage with EMBL’s outstanding research and core facilities faculty.
Vizgen Inc. is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company’s MERSCOPE® Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivalled detection efficiency at subcellular resolution. MERSCOPE® provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com or connect on social media Twitter, LinkedIn and Facebook.